Photo of Peter Schwartz

Peter Schwartz

Peter Schwartz leads the firm’s Finance practice and represents direct lenders, private equity firms and corporate borrowers in financing transactions.

He has over 25 years of experience structuring and negotiating debt financings. He also has extensive experience in M&A, private equity and venture capital, enabling him to provide clients with a broad perspective on their finance transactions.

Peter’s work covers a wide range of financial products, including senior secured, second lien and convertible loans, mezzanine debt, subordinated notes, preferred stock, and equity kickers. In addition to working on the origination of loans, he advises on debt restructurings and work-outs, forbearance arrangements, and public and private debt-for-equity exchanges.

He has worked on financings in a number of industries, including life sciences, healthcare, technology, consumer products and manufacturing. The life sciences work also includes the monetization of pharmaceutical royalty streams, which can be structured as financing or sale transactions.

Biotech companies are always searching for new ways to fund the costly and uncertain process of drug development and product launch. Over the past several years, synthetic royalty and drug development financings have become an additional option for fundraising, as traditional equity markets have remained challenging. Covington & Burling’s third

Continue Reading Synthetic Royalty and Drug Development Financings – A Funding Structure Growing in Europe

Raising capital to discover, develop, and commercialize new drugs has always been a regular feature for life sciences companies, and the current environment of tight equity markets and lower company valuations has caused significant strains. In response, many European life sciences businesses are turning to non-dilutive financing options that have

Continue Reading Non-Dilutive Financing: The U.S. Trend Catching on in Europe’s Life Sciences Sector